| Abstract CT026: Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced … J Bendell, T Bauer, M Patel, G Falchook, JL Karlix, E Lim, G Mugundu, ... Cancer Research 79 (13_Supplement), CT026-CT026, 2019 | 42* | 2019 |
| De novo transcriptome assembly for the lobster Homarus americanus and characterization of differential gene expression across nervous system tissues LL McGrath, SV Vollmer, ST Kaluziak, J Ayers BMC genomics 17, 1-16, 2016 | 42 | 2016 |
| First in Human Phase 1/2 ICONIC Trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS high CD4 T cell populations and predictors of response. TA Yap, JF Gainor, MK Callahan, GS Falchook, RK Pachynski, P LoRusso, ... Clinical Cancer Research: an Official Journal of the American Association …, 2022 | 28 | 2022 |
| Temperature preference and acclimation in the Jonah Crab, Cancer borealis L Lewis, J Ayers Journal of Experimental Marine Biology and Ecology 455, 7-13, 2014 | 27 | 2014 |
| Abstract CT011: NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with … T Cascone, R García-Campelo, J Spicer, W Weder, D Daniel, D Spigel, ... Cancer Research 82 (12_Supplement), CT011-CT011, 2022 | 26* | 2022 |
| Evidence of immune activation in the first-in-human phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors J Bendell, T Bauer, M Patel, G Falchook, JL Karlix, E Lim, G Mugundu, ... Breast 2 (5), 33, 2019 | 22 | 2019 |
| A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in … EA Lim, TM Bauer, MR Patel, GS Falchook, JL Karlix, JH Choe, ... J Clin Oncol 38 (5518), 10.1200, 2020 | 21 | 2020 |
| Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase 2 NeoCOAST Platform Trial T Cascone, G Kar, JD Spicer, R Garcia-Campelo, W Weder, DB Daniel, ... Cancer Discovery, 2023 | 17 | 2023 |
| Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 … JD Weaver, EC Stack, JA Buggé, C Hu, L McGrath, A Mueller, M Wong, ... OncoImmunology 11 (1), 2141007, 2022 | 15 | 2022 |
| Preclinical evaluation of JTX-1811, an anti-CCR8 antibody with enhanced ADCC activity, for preferential depletion of tumor-infiltrating regulatory T cells F Dépis, C Hu, J Weaver, L McGrath, B Klebanov, J Buggé, B Umiker, ... Cancer Research 80 (16 Supplement), 4532-4532, 2020 | 9 | 2020 |
| 929MO Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC … J Spicer, T Cascone, G Kar, Y Zheng, J Blando, TH Tan, M Cheng, ... Annals of Oncology 33, S971, 2022 | 8 | 2022 |
| Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors B Umiker, Y Hashambhoy-Ramsay, J Smith, T Rahman, A Mueller, ... Molecular Cancer Therapeutics 22 (4), 471-484, 2023 | 7 | 2023 |
| NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant … F Guisier, J Bennouna, AI Spira, DW Kim, BY Shim, H Abdul Sater, ... Journal of Clinical Oncology 41 (16_suppl), TPS8604-TPS8604, 2023 | 5 | 2023 |
| AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond F Comer, Y Mazor, E Hurt, C Yang, R Fleming, H Shandilya, ... Cancer Research 83 (7_Supplement), 5736-5736, 2023 | 5 | 2023 |
| Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate L McGrath, Y Zheng, S Christ, CC Sachs, S Khelifa, C Windmüller, ... Cancer Research 83 (7_Supplement), 5737-5737, 2023 | 4 | 2023 |
| Antibodies that bind chemokine (CC motif) receptor 8 (CCR8) LL Mcgrath, F Dépis, HU Changyun, LG Presta, JA Buggé US Patent 11,692,038, 2023 | 3 | 2023 |
| EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid … C Aggarwal, CG Azzoli, AI Spira, BJ Solomon, X Le, C Rolfo, D Planchard, ... Journal of Clinical Oncology 41 (16_suppl), TPS3156-TPS3156, 2023 | 3 | 2023 |
| Association of an RNA signature (RS) with emergence of ICOS hi CD4 T cells and efficacy outcomes for the ICOS agonist vopratelimab (vopra) and nivolumab (nivo) in patients (pts … TA Yap, JF Gainor, HA Burris, S Kummar, RK Pachynski, MK Callahan, ... Journal of Clinical Oncology 38 (5_suppl), 14-14, 2020 | 2 | 2020 |
| P1. 12-04 In Vivo Efficacy of AZD9592, an EGFR-cMET Bispecific ADC, in a Broad Panel of NSCLC Patient-Derived Xenograft Models L McGrath, E Rosfjord, S Christ, Y Zheng, N Floch, CC Sachs, C Cotoi, ... Journal of Thoracic Oncology 18 (11), S208, 2023 | 1 | 2023 |
| Antibodies and fusion proteins that bind to ccr8 and uses thereof LL Mcgrath, F Dépis, HU Changyun, LG Presta, JA Buggé US Patent App. 18/182,166, 2023 | 1 | 2023 |
Kris SachsenmeierCompass TherapeuticsVerified email at compasstherapeutics.com
